The National Agency for Food and Drug Administration and Control has stated that it has been informed by Novartis Nigeria in respect of the Patient Information Leaflet (PIL) of fluconazole subject to the internal review of available safety information.
According to NAFDAC “Changes were made to the Other medicines and Flunoc section; Ibrutinib (used to treat some cancers of the blood) was added to the list of medicines that may interact with Flunoc”.
NAFDAC has therefore charged patients and consumers to always read the Patient Information Leaflet of the medicines they are taking and to always inform their healthcare providers of all other medicines they are taking when medicines are being prescribed to them.
NAFDAC has advised healthcare providers to be cautious when prescribing concomitant medicines with known interactions.
NAFDAC has therefore urged healthcare providers and patients to report adverse effects experienced with the use of the product to NAFDAC.